14 January 2021

IP Considerations Protecting Next Generation Therapies Within Current Patentability Limitations

With the pharmaceutical and biotechnology industry constantly evolving, new and complex therapies are being introduced which challenge the current limitations within patentability. In order for these new innovations to be well protected the patenting process must evolve too.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

IP Considerations Protecting Next Generation Therapies Within Current Patentability Limitations

Editor's picks

Editor's picks

More features